{"id":"albuterol-emdpi-ds","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Headache"},{"rate":"3-5%","effect":"Nervousness"},{"rate":"1-3%","effect":"Palpitations"},{"rate":"1-3%","effect":"Tachycardia"},{"rate":"1-3%","effect":"Muscle cramps"}]},"_chembl":{"chemblId":"CHEMBL1441059","moleculeType":"Small molecule","molecularWeight":"576.71"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Albuterol binds to and activates beta-2 adrenergic receptors located on the smooth muscle of airways, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and bronchodilation, rapidly opening constricted airways. The eMDPI DS (electronic Metered Dose Inhaler with Dose Sensing) formulation is a device innovation that delivers albuterol via inhalation with electronic tracking and feedback capabilities.","oneSentence":"Albuterol is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:29.598Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm and reversible airway obstruction in asthma"},{"name":"Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction"}]},"trialDetails":[{"nctId":"NCT03890666","phase":"PHASE4","title":"A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2020-10-26","conditions":"Asthma","enrollment":333},{"nctId":"NCT05241288","phase":"NA","title":"Digihaler in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":54},{"nctId":"NCT04677959","phase":"PHASE4","title":"A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2021-02-16","conditions":"Asthma","enrollment":427}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Albuterol eMDPI DS","genericName":"Albuterol eMDPI DS","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Albuterol is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Acute bronchospasm and reversible airway obstruction in asthma, Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}